RxDoctor Payments Data

Alexander Hernandez, MD

Internal Medicine · Lexington, KYNPI 1144725946

Payments from drug & device makers

$871in general payments, 2019–2025

Across 48 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$316
  • Pfizer$82
  • Biohaven Pharmaceutical Holding Company Ltd.$52
  • Ultragenyx Pharmaceutical Inc.$50
  • Exact Sciences$44
  • Sanofi-aventis U.S. LLC$36
  • plus $292 from 13 others

What the payments were for

  • Food & beverage$871100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$871 in reported general payments places this provider in the 60th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$46,629
Medicare patients
144
Services billed
3,819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HumiraAdalimumab12$171,127
JardianceEmpagliflozin70$98,515
OzempicSemaglutide44$81,964
RybelsusSemaglutide15$33,119
MounjaroTirzepatide20$22,484
EliquisApixaban13$17,684
TrulicityDulaglutide13$17,486
LinzessLinaclotide12$15,283
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,802
Breo ElliptaFluticasone/Vilanterol11$7,589
MovantikNaloxegol Oxalate12$5,949
Levothyroxine Sodium201$5,891
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,227
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$4,052
Pregabalin34$2,466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira, Linzess, Synthroid$29$187,58241 claims
Novo NordiskOzempic, Rybelsus$316$115,08459 claims
Lilly USA, LLCMounjaro, Trulicity$17$39,97033 claims
PfizerEliquis$82$17,68413 claims
AstraZenecaBreztri Aerosphere$16$8,80211 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$30$5,891201 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →